LBD Diagnosis Challenges
75% of LBD patients are initially given a wrong diagnosis.
SYNTap Test Capabilities
This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.
Accurate Early Diagnosis Aids Proper Disease Management
Identifying LBD/DLB earlier in the disease can aid in making therapeutic decisions
SYNTap Biomarker Test provides clinicians with valuable information to make an early diagnosis, helping to avoid medications, which can bring on severe side effects in LBD/DLB patients.
Download the SYNTap Test Specification Sheet for details.